2022 Honorees
Anthony A. Hyman, Ph.D.
Dr. Hyman is group leader at and a director of the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden, Germany. Of his many contributions to the field of molecular biology, he is best known for two discoveries in particular: in 2000, he pioneered the use of RNA interference to define the “parts lists” for different cytoplasmic processes. In 2009, with Cliff Brangwynne and Frank Julicher, he made a fundamental breakthrough by being the first to observe that compartments in cells can form by phase separation, now known as condensates. Dr. Hyman was educated at University College London and King’s College, Cambridge, where he was awarded a Ph.D. in 1987. He is a Fellow of the Royal Society, a member of the German National Academy of Sciences Leopoldina, and a member of the National Academy of Sciences USA.
To view Dr. Hyman’s acceptance remarks: Hyman Remarks
Thomas C. Reynolds, M.D., Ph.D.
Dr. Reynolds served as Chief Medical Officer of Seattle Genetics from March 2007 until his retirement in February 2013. While at Seattle Genetics, he was responsible for building and leading an integrated clinical development, regulatory and medical affairs organization, highlighted by the development and approval of Adcetris, an antibody-drug conjugate approved to treat anaplastic large cell lymphoma and Hodgkin’s lymphoma. Previously, Dr. Reynolds served at ZymoGenetics, most recently as Vice President, Medical Affairs, where he oversaw the clinical development and regulatory filing of Recothrom, and as Vice President, Clinical Affairs at Targeted Genetics. A member of the Board of Directors of MEI Pharma since 2013, he was also a Director of Trillium Therapeutics prior to its acquisition by Pfizer in 2021. Dr. Reynolds received his M.D. and Ph.D. in Biophysics from Stanford University, and a B.A. in Chemistry from Dartmouth College.
To view Dr. Reynolds’ acceptance remarks: Reynolds Remarks